Odyssey Therapeutics (NASDAQ:ODTX) Upgraded at Zacks Research

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also issued reports on the stock. TD Cowen started coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. Wedbush started coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $30.00 target price on the stock. Oppenheimer started coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $40.00 target price on the stock. Wall Street Zen raised shares of Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. Finally, JPMorgan Chase & Co. started coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $26.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Odyssey Therapeutics Trading Up 1.9%

Shares of Odyssey Therapeutics stock opened at $17.00 on Wednesday. Odyssey Therapeutics has a 52-week low of $15.35 and a 52-week high of $20.30.

Insiders Place Their Bets

In other news, Director Nan (Ln) Li bought 1,111,111 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the acquisition, the director owned 3,333,516 shares in the company, valued at $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Shelley Chu bought 11,111 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the acquisition, the director owned 11,111 shares in the company, valued at $199,998. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 4,183,777 shares of company stock worth $75,319,986 in the last quarter.